Drug intelligence / Profile preview

porphyra enzymatic hydrolysate

Development stage: Preclinical
Lead developer: Laoshan Laboratory
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Peptides
Administration: Oral

Overview

Porphyra enzymatic hydrolysate (PEPP) is a bioactive preparation derived from the red alga *Porphyra* (specifically prepared using food-grade porphyranase combined with neutral protease). It contains oligo-porphyran and peptides. PEPP acts via the gut-joint axis to modulate the gut microbiota and enhance the production of the short-chain fatty acid propionate. Propionate subsequently suppresses inflammatory cartilage catabolism in chondrocytes by upregulating TNFAIP3 and inhibiting the NF-κB signaling pathway. It is under preclinical development for the treatment of osteoarthritis.

Other names: Porphyra enzymatic hydrolysate

Beyond the preview

Go deeper on porphyra enzymatic hydrolysate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on porphyra enzymatic hydrolysate.